Cresilon

Cresilon is a commercial-stage medical device company addressing the critical global challenge of uncontrolled bleeding through its innovative, plant-based hydrogel technology. Its flagship products, TRAUMAGEL (FDA-cleared for human trauma) and VETIGEL (for veterinary use), are designed to achieve rapid hemostasis across diverse wound geometries. The company has gained significant recognition, including being named the #1 most innovative company in medical devices by Fast Company in 2026, and is focused on expanding the adoption of its life-saving technology across pre-hospital, hospital, and veterinary care settings.

Proprietary, plant-based hydrogel polymer technology that forms a flowable gel to accelerate natural clotting and achieve rapid hemostasis in seconds, conforming to complex wound geometries without requiring manual pressure.

Cresilon competes in the global hemostats market against large, established players like Baxter (CELOX, FLOSEAL), Johnson & Johnson (SURGICEL), and Z-Medica (QuikClot). Its primary differentiation is its rapid, flowable, plant-based gel format that works without pressure, unlike many powder, sponge, or gauze-based competitors. It also competes with other advanced hemostats like fibrin sealants.